Aptose Corporate Presentation March 2022

Mar 15, 2022

Aptose Corporate Update at ASH 2021

Dec 13, 2021

2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS

Dec 13, 2021

2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML

Dec 13, 2021

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML

Dec 11, 2021

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies

Dec 11, 2021

Aptose Corporate Update at EHA 2021

Jun 11, 2021

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies

Jun 11, 2021

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS

Jun 11, 2021

Aptose Corporate Update at ASH 2020

Dec 6, 2020

• « Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• Next »